October 28, 2020 -- Arena Pharmaceuticals has launched Longboard Pharmaceuticals with $56 million in financing to support the development of the company's lead clinical and preclinical programs.
LP352 is a next-generation 5-HT2C agonist and a clinical stage program for treatment-resistant developmental and epileptic encephalopathies. Preclinical programs relating to LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor, and LP659, a centrally acting, next-generation highly selective sphingosine 1-phosphate receptor modulator, are also being developed for the potential treatment of microglial neuroinflammatory diseases.
The new company will be focused on the development of novel central nervous system-targeted assets discovered by Arena's validated G protein-coupled receptor research engine.
Longboard, formerly known as Arena Neuroscience, was a wholly owned subsidiary of Arena Pharmaceuticals.
Copyright © 2020 scienceboard.net